Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MRESVIA safely and effectively. See full prescribing information for MRESVIA. MRESVIATM (Respiratory Syncytial Virus Vaccine) injectable suspension, for intramuscular use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-other
MRESVIA is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in •individuals 60 years of age and older. •individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
- generic_name
- respiratory syncytial virus vaccine
- product_names
- Respiratory Syncytial Virus Vaccine
- ndc
- 80777-345, 80777-345-01, 80777-345-90, 80777-345-96, 80777-345-89, 80777-345-62, 80777-345-63, 80777-345-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en